Cross-sectional analysis of the humoral response after SARS-CoV-2 vaccination in Sardinian multiple sclerosis patients, a follow-up study.
BNT162b2 messenger RNA (mRNA)
COVID-19
COVID-19 vaccination
SARS-CoV-2
disease-modifying therapy (DMT)
humoral immunity
multiple sclerosis
vaccine efficacy and effectiveness
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
17
05
2022
accepted:
01
08
2022
entrez:
5
9
2022
pubmed:
6
9
2022
medline:
9
9
2022
Statut:
epublish
Résumé
Monitoring immune responses to SARS-CoV-2 vaccination and its clinical efficacy over time in Multiple Sclerosis (MS) patients treated with disease-modifying therapies (DMTs) help to establish the optimal strategies to ensure adequate COVID-19 protection without compromising disease control offered by DMTs. Following our previous observations on the humoral response one month after two doses of BNT162b2 vaccine (T1) in MS patients differently treated, here we present a cross-sectional and longitudinal follow-up analysis six months following vaccination (T2, n=662) and one month following the first booster (T3, n=185). Consistent with results at T1, humoral responses were decreased in MS patients treated with fingolimod and anti-CD20 therapies compared with untreated patients also at the time points considered here (T2 and T3). Interestingly, a strong upregulation one month after the booster was observed in patients under every DMTs analyzed, including those treated with fingolimod and anti-CD20 therapies. Although patients taking these latter therapies had a higher rate of COVID-19 infection five months after the first booster, only mild symptoms that did not require hospitalization were reported for all the DMTs analyzed here. Based on these findings we anticipate that additional vaccine booster shots will likely further improve immune responses and COVID-19 protection in MS patients treated with any DMT.
Identifiants
pubmed: 36059537
doi: 10.3389/fimmu.2022.946356
pmc: PMC9433902
doi:
Substances chimiques
COVID-19 Vaccines
0
Fingolimod Hydrochloride
G926EC510T
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
946356Informations de copyright
Copyright © 2022 Idda, Pitzalis, Lodde, Loizedda, Frau, Lobina, Zoledziewska, Virdis, Delogu, Marini, Mingoia, Masala, Lorefice, Fronza, Carmagnini, Carta, Pilotto, Castiglia, Chessa, Uzzau, Farina, Solla, Steri, Devoto, Fiorillo, Floris, Zarbo, Cocco and Cucca.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Med. 2021 Aug;27(8):1370-1378
pubmed: 34108716
J Neurol. 2022 May;269(5):2286-2292
pubmed: 35235002
Front Immunol. 2021 Dec 09;12:781843
pubmed: 34956211
Mult Scler. 2021 May;27(6):864-870
pubmed: 33856242
Cell Rep Med. 2021 Jul 20;2(7):100354
pubmed: 34250512
Nat Med. 2022 Jul;28(7):1486-1490
pubmed: 35468276
Front Immunol. 2022 Apr 01;13:868915
pubmed: 35432335
JAMA Neurol. 2021 Dec 1;78(12):1510-1514
pubmed: 34554197
Diabetes Metab Res Rev. 2022 Jan;38(1):e3465
pubmed: 33955644
J Neurol Sci. 2022 Mar 15;434:120155
pubmed: 35091386
Nat Genet. 2019 Feb;51(2):237-244
pubmed: 30643251
Vaccines (Basel). 2022 Apr 28;10(5):
pubmed: 35632451
EBioMedicine. 2022 Jan;75:103805
pubmed: 35032961
Mult Scler. 2022 Jun;28(7):1138-1145
pubmed: 35475363
EBioMedicine. 2021 Oct;72:103581
pubmed: 34563483
Nat Med. 2021 Nov;27(11):1990-2001
pubmed: 34522051
Nat Commun. 2021 Oct 29;12(1):6250
pubmed: 34716320
J Neurol. 2022 Jul 26;:
pubmed: 35879563
EClinicalMedicine. 2021 Jun;36:100902
pubmed: 34056568
Curr Opin Neurol. 2021 Jun 1;34(3):322-328
pubmed: 33709979